Mylan is taking another hit tied to its EpiPen pricing controversy.

Allergan CEO Brent Saunders is tired of hearing from investors that chin-fat buster Kybella’s launch isn’t going as well as those of his company's other…

Johnson & Johnson and Actelion reportedly have settled a key condition of their long-discussed transaction: price.

AbbVie joined the 10% price-hike pledge Wednesday, following Allergan and Novo Nordisk, as the drug pricing debate sent biopharma shares reeling once again.…

Two months after U.S. lawmakers called for an investigation into the insulin market, Novo Nordisk faces a potential class-action lawsuit for its role in…

The J.P. Morgan Healthcare Conference is starting to wind down in San Francisco, but that doesn't mean the news has diminished.

Deal talk is pretty hard to ignore at the J.P. Morgan Healthcare Conference—especially for a pair of the world’s biggest hemophilia drugmakers.

Remember the Trump euphoria that hit biopharma stocks in November? Well, scratch that. 

Merck & Co. is another step closer to eclipsing its I-O competitors thanks to an unexpectedly quick filing for a new Keytruda-chemo combo.